Skip to main content

Glaucoma Debate Club: Cases in Sustained IOP Control - Thursday, March 4, 2021 [248]


Virtual CME Symposium

Thursday, March 4, 2021
5:00 PM PST | 6:00 PM MST | 7:00 PM CST | 8:00 PM EST

NOTE: You will be asked to "sign in" or "sign up" to register for the program and then complete a brief pretest. Once you submit your answers, choose "next item". Upon registration, a link to access the symposium will be sent in a confirmation email.

Please contact info@mededicus.com with any questions. Thank you!

FACULTY
Ike K. Ahmed, MD, FRCSC (Chair)
Assistant Professor
Fellowship Director, Glaucoma and Anterior Segment Surgery (GAASS) Fellowship
Research Director, Kensington Eye Institute
University of Toronto
Toronto, Canada
Division Head, Ophthalmology
Trillium Health Partners
Mississauga, Canada
Leon W. Herndon Jr, MD
Professor of Ophthalmology
Chief, Glaucoma Division
Duke Eye Center
Durham, North Carolina
Marlene R. Moster, MD
Professor of Ophthalmology
Thomas Jefferson University School of Medicine
Attending Surgeon, Glaucoma Service
Wills Eye Hospital
Philadelphia, Pennsylvania
Oluwatosin (Tosin) U. Smith, MD
Attending Clinician and Surgeon
Glaucoma Associates of Texas
Associate Professor of Ophthalmology
University of Texas Southwestern Medical Center
Dallas, Texas

CONTINUING MEDICAL EDUCATION INFORMATION

Activity Description and Purpose
The successful treatment of glaucoma is challenged by many factors, including patient nonadherence to topical therapies, waning efficacy of topical therapies as disease progresses, and risks associated with traditional glaucoma surgery. As a result, several new approaches have been introduced, including sustained drug-eluting devices and minimally invasive surgical procedures. The choice of intervention is not straightforward, and a nuanced, patient-centered approach to selection is needed. In this educational activity, experts will use cases and a debate-style format to explore different treatment options for a variety of patient scenarios. The desired results of this educational activity are to enable glaucoma specialists and other ophthalmologists to confidently incorporate various new treatments beyond topical drugs to improve visual outcomes for patients with glaucoma.

Target Audience

This educational activity is intended for glaucoma specialists and other ophthalmologists caring for patients with glaucoma.

Learning Objectives
After completing this activity, participants will be better able to:
  • Review safety and efficacy data for approved and emerging sustained drug delivery devices for glaucoma
  • Identify patients with glaucoma who are most likely to benefit from sustained drug delivery treatment
  • Choose appropriate MIGS procedures for a variety of patient scenarios

Accreditation Statement
MedEdicus is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
MedEdicus designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Obtaining Credit
To obtain AMA PRA Category 1 Credit™ for this activity, participate in the meeting, consult referenced sources as necessary, and complete the posttest and evaluation online. After completing the posttest and evaluation, a certificate will be made available immediately.

Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.

Faculty
Ike K. Ahmed, MD, is a consultant for Aequus BioPharma, Inc, Aerie Pharmaceuticals, Inc, Akorn, Inc, Alcon, Allergan, Aquea Health, Inc, ArcScan, Inc, Bausch & Lomb Incorporated, Beaver-Visitec International, Beyeonics Surgical Ltd, Camras Vision, Inc, Carl Zeiss Meditec, Inc, CorNeat Vision Ltd, Ellex, ELT Sight, Inc, ElutiMed, Equinox, Genentech, Inc, Glaukos Corporation, Injectsense, Inc, IRIDEX Corporation, iSTAR, Ivantis Inc, Johnson & Johnson Vision Care, Inc, Kelotec Inc, LayerBio, Inc, Leica Microsystems, Long Bridge Medical, Inc, MicroOptx, MicroSurgical Technology, Minosys Cellular Devices Inc, New World Medical, Inc, Ocular Instruments, Ocular Therapeutix, Inc, Omega Ophthalmics, Polyactiva Pty Ltd, Ripple Therapeutics, Sanoculis Ltd, Santen Inc, ScienceBased Health, Sight Sciences, Smartlens, Inc, Strõma Medical Corporation, Thea Pharmaceuticals Limited, ViaLase, Inc, Vizzario, and W. L. Gore & Associates, Inc; is a contracted researcher for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Camras Vision, Inc, Glaukos Corporation, Ivantis Inc, Johnson & Johnson Vision Care, Inc, New World Medical, Inc, and Santen Inc; and is on the speakers bureau for Alcon, Allergan, Carl Zeiss Meditec, Inc, Johnson & Johnson Vision Care, Inc, MicroSurgical Technology, and Mundipharma International.

Leon W. Herndon Jr, MD,
is a consultant for Alcon, Allergan, Equinox, Glaukos Corporation, New World Medical, Inc, Ocular Therapeutix, Inc, and Santen Inc; is on the speakers bureau for New World Medical, Inc; is a contracted researcher for Ocular Therapeutix, Inc; and has ownership interest in Sight Sciences.

Marlene R. Moster, MD,
is a consultant for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Qura Therapeutics, and Santen Inc; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, IRIDEX Corporation, and Novartis Pharmaceuticals Corporation; is a contracted researcher for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Glaukos Corporation, InnFocus, Inc, IRIDEX Corporation, Nicox, and Santen Inc; and has ownership interest in Qura Therapeutics.

Oluwatosin (Tosin) U. Smith, MD,
is a consultant for Aerie Pharmaceuticals, Inc; Allergan; Bausch & Lomb Incorporated; Glaukos Corporation; New World Medical, Inc; and Santen Inc; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Allergan, and Bausch & Lomb Incorporated; and is a contracted researcher for Allergan, New World Medical, Inc, and Santen Inc.

Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial financial relationships to disclose.

Planners and Managers

MedEdicus planners and managers have no relevant commercial relationships to disclose.

Disclosure of Commercial Support
This continuing medical education activity is supported through an unrestricted educational grant from Allergan.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Allergan.

This CME activity is copyrighted to MedEdicus LLC © 2021. All rights reserved. 248